An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
CADTH Canadian Drug Expert Committee Recommendation: Cladribine (Mavenclad — EMD Serono): Indication: Relapsing-Remitting Multiple Sclerosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active Crohn disease who have demonstrated prior treatment failure; that is., an inadequate response to, loss of response to, or intolerance to at least one conventional and/or biologic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Upadacitinib may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs [Internet].
Non-Hodgkin's Lymphoma: Diagnosis and Management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. Upadacitinib can be used with or without topical corticosteroids [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.
Abrocitinib (Cibinqo): CADTH Reimbursement Recommendation: Indication: For the treatment of patients aged 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs (e.g., steroid or biologic), or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Abemaciclib (Verzenio): CADTH Reimbursement Recommendation: Indication: In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score of at least 20% [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Lutetium (177Lu) Oxodotreotide (Lutathera): CADTH Reimbursement Recommendation: Indication: For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance [Internet].
Tafasitamab (Minjuvi): CADTH Reimbursement Recommendation: Indication: In combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from low grade lymphoma, who are not eligible for autologous stem cell transplant [Internet].
Ozanimod (Zeposia): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Dec.
Lurbinectedin (Zepzelca): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with stage III or metastatic small cell lung cancer who have progressed on or after platinum-containing therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least 1 of conventional and/or biologic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Sep.
Deucravacitinib (Sotyktu): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Recommendation: Indication: Treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].
COVID-19 rapid guideline: delivery of radiotherapy.
London: National Institute for Health and Care Excellence (NICE); 2021 Feb 12. (NICE Guideline, No. 162.)
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on